/

2348.HK

DAWNRAYS PHARMAClosed

0.9900+0.03 +3.13%HKD

HKSE · as of Oct 14, 03:19 ET · 15m delay

Open

0.9500

Prev close

0.9600

Day range

0.95000.9900

52-week range

0.94001.25

Volume

952.00K5.82×

Mkt cap

1.49B

P/E ttm

5.82

Fwd P/E

2.25

EPS ttm

0.1700

Div yield

6.56%

Earnings

—

From 52w high

−20.80%

Price Chart

Yahoo Finance · delayed

2348.HKOct 14, 2026O 0.9500H 0.9900L 0.9500C 0.9900+0.0300 (+3.13%)Vol 952.00K

SMA 500.9884
SMA 2001.0835

1Y change −18.18% since Oct 13, 2025 close529 bars loadedTimes in Asia/Hong_KongDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

2348.HK DAWNRAYS PHARMA · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: +3.13%
1 month: +0.51%
3 months: −1.00%
6 months: −10.81%
Year to date: −18.85%
1 year: −18.85%

Valuation & ownership

Market cap: 1.49B
Enterprise value: −362.42M
P/E (ttm): 5.82
Forward P/E: 2.25
PEG ratio: —
Price / book: 0.37
Price / sales (ttm): 1.30
EV / EBITDA: -1.01
EPS (ttm): 0.1700
EPS (forward): 0.4400
Beta (5y monthly): 0.26
Dividend yield: 6.56%
Payout ratio: 36.93%
Shares outstanding: 1.51B
Float: 489.94M
Short % of float: —
Short ratio (days): —
Held by insiders: 67.47%
Held by institutions: 3.18%
Avg volume (3m): 163.56K
50-day average: 0.9892
200-day average: 1.08
52-week change: −18.85%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): 58.2
vs 50-day SMA: +0.16%
vs 200-day SMA: −8.63%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▲ above
ATR (14) % of price: 1.32%
Realised vol (20d, ann.): 13.7%
From 52-week high: −20.80%
From 52-week low: +5.32%

ANR

Analyst Consensus

No analyst coverage for this instrument.

Financial Snapshot

Full statements →trailing twelve months

Revenue (ttm): 1.15B
Revenue growth (yoy): −13.40%
Earnings growth (yoy): +17.80%
Gross margin: 45.44%
Operating margin: 21.20%
Profit margin: 20.30%

DES

About DAWNRAYS PHARMA

Yahoo Finance profile

Dawnrays Pharmaceutical (Holdings) Limited, an investment holding company, develops, manufactures, and sells non-patented pharmaceutical medicines in Mainland China and internationally. It operates in two segments, Intermediates and Bulk Medicines, and Finished Drugs. The company offers antibiotics, including pharmaceutical intermediates, bulk medicines, powder for injections, cephalosporin tablets, and other oral solid-dosage-form antibiotics. It also provides system specific medicines for various therapeutic areas, such as cardiovascular systems; anti-HBV, anti-allergic, and digestive systems; urinary systems; anti-hypertensive, antihyperlipidemic, and antiviral; and endocrine system drugs. The company was founded in 1995 and is headquartered in Wan Chai, Hong Kong.

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Employees: 1,074
Headquarters: Wan Chai, Hong Kong
Website: dawnrays.com
Officers: Ms. Kei Ling Li Co-Founder & Executive Chairman
Ms. Liwei Yu Chief Executive Officer
Mr. Yung Lai Hung Co-Founder & Executive Director
Mr. Yi Jun Wu Chief Financial Officer

SEAS

Seasonality · 2348.HK

2007–2026 · monthly returns

Strongest month Apr +4.62%Weakest month Aug −2.48%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-4.9	2.6	-9.2	4.6	-7.1	-2.9	2.0	-1.9	-4.4	1.5			−18.9%
2025	-1.6	-2.5	2.6	-3.3	5.2	1.6	11.3	-8.7	-6.3	1.7	4.2	-2.4	−0.0%
2024	6.7	5.4	-0.8	0.9	0.8	1.7	-5.8	-1.8	7.1	4.2	-4.0	1.7	+16.2%
2023	-2.3	0.0	-0.8	3.9	-7.5	-3.2	1.7	-6.6	-2.6	0.0	-5.4	0.0	−21.1%
2022	-13.2	-7.6	-3.0	-13.1	0.9	12.3	0.0	-5.5	-13.2	0.0	5.7	19.8	−20.4%
2021	-13.7	9.2	12.2	8.2	17.6	-3.7	-1.1	-9.6	4.3	1.2	0.0	-1.8	+20.1%
2020	1.4	-9.0	-12.9	0.9	-19.8	-2.2	-2.2	4.5	2.2	-7.4	25.0	26.4	−2.8%
2019	6.1	5.1	-10.4	-2.7	0.0	1.4	2.8	-9.4	10.4	-6.7	0.7	2.1	−2.7%
2018	5.2	-4.9	0.7	4.0	8.5	0.2	-7.8	-4.0	-15.8	-0.6	8.3	-24.6	−31.1%
2017	1.9	-6.5	1.6	1.1	-3.5	15.5	-7.5	-0.9	-3.4	2.7	-9.1	1.7	−8.4%
2016	-12.8	0.6	17.2	3.1	-3.3	-4.1	-14.2	6.7	-6.5	-8.5	2.2	-1.7	−22.6%
2015	8.1	-12.9	20.2	17.0	13.7	-10.1	12.1	-18.5	9.0	-3.3	-6.0	-0.7	+21.6%
2014	14.6	0.9	-3.2	6.3	-1.5	-2.2	11.3	1.7	16.2	3.5	-5.5	-32.0	+0.4%
2013	7.3	5.1	12.4	12.5	17.9	-15.9	14.7	12.4	16.1	10.7	12.0	14.7	+200.6%
2012	-2.2	1.8	-9.4	-2.5	-7.1	0.5	-4.9	10.8	-15.4	-0.6	-6.1	6.5	−27.1%
2011	-9.6	1.5	-9.9	-4.6	-10.4	7.4	4.0	-4.9	-23.0	6.6	2.2	-2.2	−38.4%
2010	9.6	-2.9	26.3	39.3	-10.7	0.5	8.1	-0.9	67.1	-8.2	-2.6	8.6	+192.0%
2009	-1.4	-1.4	11.8	6.6	1.2	9.8	4.4	-2.1	4.3	7.3	18.4	2.5	+78.6%
2008	-7.5	8.1	1.2	6.2	-7.0	1.2	-4.9	-1.3	-2.6	-10.8	6.1	0.0	−12.5%
2007	8.9	-2.3	-15.5	4.2	-1.4	12.3	4.9	-9.3	6.4	-6.0	-6.4	9.6	+1.3%

INSD

Insider Activity · 2348.HK

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
May 13, 2026	Yu (Liwei)Chief Executive Officer	Conversion at price 0.11 per share.	1.28M	$147.53K
May 22, 2025	Li (Kei Ling)Chairman of the Board	Acquisition at price 0.15 per share.	60K	$9.26K
May 14, 2025	Li (Kei Ling)Chairman of the Board	Acquisition at price 0.15 per share.	76K	$11.29K
May 13, 2025	Li (Kei Ling)Chairman of the Board	Acquisition at price 0.15 per share.	12K	$1.78K
May 12, 2025	Li (Kei Ling)Chairman of the Board	Acquisition at price 0.15 per share.	60K	$8.92K
May 11, 2025	Li (Kei Ling)Chairman of the Board	Acquisition at price 0.15 per share.	80K	$11.90K
May 8, 2025	Li (Kei Ling)Chairman of the Board	Acquisition at price 0.15 per share.	48K	$7.16K

2348.HK

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

2348.HK

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About DAWNRAYS PHARMA

Seasonality · 2348.HK

Insider Activity · 2348.HK

Congress Trades · 2348.HK

Investors Holding 2348.HK

Investors Holding 2348.HK

Congress Trades · 2348.HK

Insider Activity · 2348.HK

Seasonality · 2348.HK

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About DAWNRAYS PHARMA

Earnings & Dividends

News